Salute e Benessere
Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients
In the intention-to-treat population (118 participants), safety and tolerability were not significantly different between groups. In the secondary outcomes, MUNIX showed a significantly reduced decline with Fasudil 60 mg at 26 and 90 days, and for Fasudil 30 mg at 90 days after treatment initiation. In addition, there was a directional difference in a slower loss of SVC favoring the 60 mg of fasudil treatment at day 26, which was statistically significant in a post-hoc subgroup analysis of females at all time points, as stated in the conference abstract.
The authors, who include the principal investigators of this investigator-initiated trial, conclude the following regarding the results of this trial in the abstract:
These preliminary results were shared in the conference abstract and have not yet been peer-reviewed.
said Anjan Aralihalli, President and founder of Raya.
Based on these encouraging findings, Raya will now test fasudil in more extensive studies with a larger patient cohort to further assess the compound's efficacy in ALS. In addition, Raya has reformulated fasudil into a novel formulation to enhance ease of use, especially for the approximately 80% of ALS patients that suffer from dysphagia.
Anjan Aralihalli continues:
For more information about Raya and its innovative pipeline, visit www.rayatherapeutic.com or LinkedIn
Members of the Raya management team will be attending the ENCALS Annual Meeting in Stockholm, Sweden from June 17-20. https://www.encals.eu/meetings/stockholm/
Raya is a mission-driven company focused on the treatment of ALS, leveraging the latest techniques for the selection and development of disease-modifying therapies. The company has a robust pipeline of five distinct clinical stage compounds that each target different pathways involved in motor neuron degeneration seen in ALS patients. The compounds were in-licensed following a rigorous selection process based on biological plausibility, clinical target engagement and functional clinical effects reflective of efficacy. This diversified approach may enable the development of combination therapies which may have a significant impact on disease progression. To develop further combination therapies, Raya entered into a strategic research collaboration with argenx last summer (https://www.prnewswire.com/in/news-releases/raya-therapeutic-announces-early-stage-rd-collaboration-with-argenx-301874999.html). This partnership explores synergistic effects of their combined drug candidates in the hope of developing more effective treatment options for ALS patients. Raya is further supported by global experts and will leverage a unique patient-friendly platform trial design offering new hope in the fight against ALS.
Fasudil is a small molecule inhibitor of the rho-associated kinase (ROCK) and is approved for the treatment of subarachnoid hemorrhage in a few Asian countries. In preclinical studies, fasudil attenuates neurodegeneration, modulates neuroinflammation, and fosters axonal regeneration.
The UMG located in Göttingen, Lower Saxony, Germany is one of the leading university medical facilities in Germany . It is comprised of a Medical Faculty engaged in research and teaching, a University Hospital providing patient care and Research allowing for the swift transfer of innovative therapy options into patient care and education.
Contact Information for Media Inquiries: admin@rayatherapeutic.com
Logo - https://mma.prnewswire.com/media/2439540/Raya_Therapeutic_Inc__Raya_Therapeutic_Announces_Supportive_Clin.jpg
View original content:https://www.prnewswire.co.uk/news-releases/raya-therapeutic-announces-supportive-clinical-results-of-fasudil-rt1968-in-als-patients-302173497.html